menu
    • menu
    [{"orgOrder":0,"company":"Moksha8 Pharmaceuticals","sponsor":"JANSSEN BIOTECH","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Agreement","leadProduct":"Methylphenidate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Moksha8 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Moksha8 Pharmaceuticals \/ Janssen Biotech","highestDevelopmentStatusID":"15","companyTruncated":"Moksha8 Pharmaceuticals \/ Janssen Biotech"},{"orgOrder":0,"company":"Neos Therapeutics","sponsor":"Aytu BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Merger","leadProduct":"Methylphenidate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Neos Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0.040000000000000001,"dosageForm":"Oral Tablet","sponsorNew":"Neos Therapeutics \/ Aytu BioPharma","highestDevelopmentStatusID":"15","companyTruncated":"Neos Therapeutics \/ Aytu BioPharma"},{"orgOrder":0,"company":"Purdue Pharmaceuticals L.P","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Methylphenidate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Purdue Pharmaceuticals L.P","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Purdue Pharmaceuticals L.P \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Purdue Pharmaceuticals L.P \/ Inapplicable"},{"orgOrder":0,"company":"JPM van Stralen Medicine Professional","sponsor":"Purdue Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Methylphenidate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"JPM van Stralen Medicine Professional","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"JPM van Stralen Medicine Professional \/ Purdue Pharma","highestDevelopmentStatusID":"11","companyTruncated":"JPM van Stralen Medicine Professional \/ Purdue Pharma"},{"orgOrder":0,"company":"Purdue Pharmaceuticals L.P","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Methylphenidate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Purdue Pharmaceuticals L.P","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Purdue Pharmaceuticals L.P \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Purdue Pharmaceuticals L.P \/ Inapplicable"},{"orgOrder":0,"company":"Aytu BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Methylphenidate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Aytu BioPharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Disintegrating, Extended Release","sponsorNew":"Aytu BioPharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aytu BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"VA Office of Research and Development","sponsor":"VA New York Harbor Healthcare System | Portland VA Medical Center | Miami VA Healthcare System | VA Boston Healthcare System","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Methylphenidate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Neurology","graph2":"Phase IV","graph3":"VA Office of Research and Development","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VA Office of Research and Development \/ VA New York Harbor Healthcare System | Portland VA Medical Center | Miami VA Healthcare System | VA Boston Healthcare System","highestDevelopmentStatusID":"11","companyTruncated":"VA Office of Research and Development \/ VA New York Harbor Healthcare System | Portland VA Medical Center | Miami VA Healthcare System | VA Boston Healthcare System"},{"orgOrder":0,"company":"Ariel University","sponsor":"Maccabi Healthcare Services, Israel","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Methylphenidate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Ariel University","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ariel University \/ Maccabi Healthcare Services, Israel","highestDevelopmentStatusID":"9","companyTruncated":"Ariel University \/ Maccabi Healthcare Services, Israel"},{"orgOrder":0,"company":"The Royal Ottawa Mental Health Centre","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Methylphenidate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"The Royal Ottawa Mental Health Centre","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Royal Ottawa Mental Health Centre \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"The Royal Ottawa Mental Health Centre \/ Inapplicable"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Methylphenidate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Neurology","graph2":"Undisclosed","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunnybrook Health Sciences Centre \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Sunnybrook Health Sciences Centre \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Concerta, Methylin, Ritalin

    Menu

    Concerta, Methylin, Ritalin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Aytu BioPharma

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            Aytu BioPharma

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methylphenidate

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Aytu BioPharma Announces Approval of the Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplem...

                            Details : Cotempla XR-ODT (methylphenidate extended-release orally disintegrating tablets) is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 17 years of age.

                            Product Name : Cotempla

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            October 26, 2023

                            Lead Product(s) : Methylphenidate

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sunnybrook Health Sciences Centre

                            Country arrow
                            Peptide Process CMC
                            Not Confirmed

                            Sunnybrook Health Sciences Centre

                            Country arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methylphenidate

                            Therapeutic Area : Neurology

                            Study Phase : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            rTMS for Apathy Clinical Trial

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            September 30, 2022

                            Lead Product(s) : Methylphenidate

                            Therapeutic Area : Neurology

                            Highest Development Status : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            The Royal Ottawa Mental Health Centre

                            Country arrow
                            Peptide Process CMC
                            Not Confirmed

                            The Royal Ottawa Mental Health Centre

                            Country arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methylphenidate

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Adjunctive Methylphenidate ER in Patients With Schizophrenia to Improve Functional and Cognitive Outcomes

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            June 10, 2022

                            Lead Product(s) : Methylphenidate

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Ariel University

                            Country arrow
                            Peptide Process CMC
                            Not Confirmed

                            Ariel University

                            Country arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methylphenidate

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Maccabi Healthcare Services, Israel

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Assessing Cognitive Performance Among Adults With Attention Disorders Working on Treadmill

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            February 16, 2022

                            Lead Product(s) : Methylphenidate

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Maccabi Healthcare Services, Israel

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Purdue Pharmaceuticals L.P

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            Purdue Pharmaceuticals L.P

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methylphenidate

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase IV

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Tolerability Study of Adhansia XR® Extended-Release Capsules in Children

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            August 03, 2021

                            Lead Product(s) : Methylphenidate

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase IV

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            JPM van Stralen Medicine Professional

                            Country arrow
                            Peptide Process CMC
                            Not Confirmed

                            JPM van Stralen Medicine Professional

                            Country arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methylphenidate

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase IV

                            Sponsor : Purdue Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of the Effect Foquest® on Sleep in Children Aged 6-12 With ADHD

                            Details : Undisclosed

                            Product Name : Foquest

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            February 05, 2021

                            Lead Product(s) : Methylphenidate

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase IV

                            Sponsor : Purdue Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Neos Therapeutics

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            Neos Therapeutics

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methylphenidate

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved FDF

                            Sponsor : Aytu BioPharma

                            Deal Size : $44.9 million

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Aytu BioScience and Neos Therapeutics Announce Definitive Merger Agreement

                            Details : Aytu adds Neos' established, multi-brand ADHD portfolio which includes Adzenys XR-ODT and Cotempla XR-ODT, enhancing Aytu's footprint in pediatrics and expanding its presence in adjacent specialty care segments.

                            Product Name : Cotempla XR-ODT

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            October 12, 2020

                            Lead Product(s) : Methylphenidate

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved FDF

                            Sponsor : Aytu BioPharma

                            Deal Size : $44.9 million

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Moksha8 Pharmaceuticals

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            Moksha8 Pharmaceuticals

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methylphenidate

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved FDF

                            Sponsor : JANSSEN BIOTECH

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Moksha8 Pharmaceuticals Announces Strategic Partnership with Janssen for Selected CNS Portfolio in Mexico

                            Details : The strong and diverse portfolio includes: CONCERTA®, HALDOL®, HALDOL® DECANOAS, REMINYL®, SIBELIUM®, RISPERDAL®, RISPERDAL CONSTA® and TOPAMAX®.

                            Product Name : Concerta

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            September 29, 2020

                            Lead Product(s) : Methylphenidate

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved FDF

                            Sponsor : JANSSEN BIOTECH

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Purdue Pharmaceuticals L.P

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            Purdue Pharmaceuticals L.P

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methylphenidate

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase IV

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Real-World Evidence of Duration of Effect of Adhansia XR (Extended-Release) for Treatment of Attention-Deficit...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            August 11, 2020

                            Lead Product(s) : Methylphenidate

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase IV

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            VA Office of Research and Development

                            Country arrow
                            Peptide Process CMC
                            Not Confirmed

                            VA Office of Research and Development

                            Country arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methylphenidate

                            Therapeutic Area : Neurology

                            Study Phase : Phase IV

                            Sponsor : VA New York Harbor Healthcare System | Portland VA Medical Center | Miami VA Healthcare System | VA Boston Healthcare System

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            June 05, 2020

                            Lead Product(s) : Methylphenidate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase IV

                            Sponsor : VA New York Harbor Healthcare System | Portland VA Medical Center | Miami VA Healthcare System | VA Boston Healthcare System

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth